Cited by 466Chronic Kidney Disease and DiabetesHormonal Regulation and HypertensionRenin-Angiotensin System Studies

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

Sato, Atsuhisa, Hayashi, Koichi, Naruse, Mitsuhide, Saruta, Takao·2003·Hypertension

Open this paper in CoChat — free account

Abstract

It has been reported that continuous ACE inhibitor therapy does not necessarily produce a maintained decrease in plasma aldosterone levels, which may remain high or increase eventually during long-term use (aldosterone escape). We have examined the role of aldosterone escape in 45 patients with type 2 diabetes and early nephropathy treated with an ACE inhibitor for 40 weeks. With treatment, there was a 40% reduction in average urinary albumin excretion, although urinary albumin excretion in patients with aldosterone escape (18 patients) was significantly higher than that in patients without escape (27 patients). In the 18 patients with escape, spironolactone (25 mg/d) was added to ACE inhibitor treatment in 13. After a 24-week study period, urinary albumin excretion and left ventricular mass index were significantly reduced without blood pressure change. In conclusion, the present study demonstrates that aldosterone escape is observed in 40% of patients with type 2 diabetes with early nephropathy despite the use of ACE inhibitors. Our study suggests the possibility that aldosterone blockade may represent optimal therapy for patients with early diabetic nephropathy who show aldosterone escape during ACE inhibitor treatment and who no longer show maximal antiproteinuric effects of ACE inhibition. Additional, larger, prospectively randomized, double-blind studies will be needed before adaptation of this strategy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000044937.95080.e9

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339

Flagged first, then by citations

Show all 0 references

Research works printed but not linked: 27

10.1172/JCI104436 · DOI
10.3109/10641969709083193 · DOI
Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med. 1992; 120: 893–901.
10.1291/hypres.23.25 · DOI
10.1177/147323000102900103 · DOI
10.1291/hypres.24.99 · DOI
10.1291/hypres.22.17 · DOI
10.1097/00004872-200105000-00001 · DOI
10.1210/endo.141.10.7711 · DOI
10.1161/hyp.35.5.1078 · DOI
10.1161/circ.100.10.1134 · DOI
10.1053/ajkd.2001.22069 · DOI
Guidelines Subcommittee. World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999; 1999: 17:151–183.
10.1001/archinte.1987.00370050135022 · DOI
10.1056/NEJM198312223092503 · DOI
10.2337/diacare.25.2007.S85 · DOI
10.1161/01.CIR.58.6.1072 · DOI
10.1161/01.CIR.55.4.613 · DOI
10.1016/0002-9149(82)90390-3 · DOI
10.1016/S1071-9164(96)80009-1 · DOI
10.1002/j.1552-4604.1993.tb03901.x · DOI
10.1016/S0735-1097(01)01714-4 · DOI
10.1016/S0735-1097(01)01237-2 · DOI
10.1056/NEJM200109203451215 · DOI
Arutyunov G, Chernyavskaya T, Korsunskaya M, Rylova A. Study of the efficacy and safety of RAAS long-term complete blockade in type II diabetic patients with MAU and essential hypertension. Eur Heart J. 2000; 21: 91.Abstract.
10.1046/j.1523-1755.2000.00055.x · DOI
10.1210/endo.137.10.8828470 · DOI

Sorted by citations

Items 301–400 of 435

Vasoactive Hormones and the Diabetic Kidney
Maric, C. (2008) · TheScientificWorldJournal · doi:10.1100/tsw.2008.57 · Cited by 10
“Long-term ACE inhibition or ARBs are associated with increases in plasma aldosterone levels in some patients after an initial reduction or unchanged levels[28,92].”
The Role of Aldosterone Blockers in the Management of Chronic Heart Failure
Coca, S. G., & Perazella, M. A. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200510000-00005 · Cited by 7
Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Alexandrou, M. E., Theodorakopoulou, M. P., & Sarafidis, P. A. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020019 · Cited by 12
“, 2003 [63] Open-label, single-arm study 24 weeks 13 T2DM, UACR 30–300 mg/g and creatinine clearance > 60 mL/min Trandolapril ↓ UAE and LVMI for spironolactone (p < 0.”
Background
Histone demethylase LSD1 deficiency and biological sex: impact on blood pressure and aldosterone production
Huang, Y., Ting, P. Y., Yao, T. M., Homma, T., Brooks, D. L. P., Rangel, I. K., Adler, G. K., Romero, J. R., Williams, J. S., Pojoga, L. H., et al. (2018) · Journal of Endocrinology · doi:10.1530/joe-18-0247 · Cited by 13
Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
Inampudi, C., Alvarez, P. A., Asleh, R., & Briasoulis, Α. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123164916 · Cited by 10
“Multiple animal and human studies have shown that despite the Renin-angiotensin-aldosterone blockade, aldosterone breakthrough leads to progression of renal and cardiac disease supporting the role of MRA in this patient population [44-49].”
Background
Pathophysiology and Pathogenesis of Diabetic Nephropathy
Chen, S., Khoury, C. C., & Ziyadeh, F. N. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00078-1 · Cited by 9
Aldosterone synthase (CYP11B2) −344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients
Lajer, M., Schjoedt, K. J., Jacobsen, P., Tarnow, L., & Parving, H. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01871.x · Cited by 9
Clinical Properties and Non-Clinical Testing of Mineralocorticoid Receptor Antagonists in In Vitro Cell Models
Varda, L., Ekart, R., Lainščak, M., Maver, U., & Bevc, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169088 · Cited by 9
“In numerous clinical studies, spironolactone and eplerenone have shown favourable antiproteinuric effects in addition to ACEi or ARBs, especially in patients with diabetic kidney disease [65–67].”
Background
Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression
Cavallari, L., Fashingbauer, L. A., Camp, J. R., King, S. T., & Geenen, D. (2008) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320308096367 · Cited by 8
Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients
Ko, G. J., Kang, Y. S., Lee, M., Song, H. K., Kim, H. K., & Cha, D. R. (2008) · Nephrology · doi:10.1111/j.1440-1797.2008.01005.x · Cited by 7
Pharmacological management of renal fibrotic disease
Gaedeke, J., Neumayer, H., & Peters, H. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.377 · Cited by 6
“Moreover, aldosterone inhibition by spironolactone was associated with further reductions of proteinuria in patients on ACEi therapy, either with or without signs of aldosterone escape [61,62].”
Background
Hypertension Treatment Guidelines: Practical Implications
Choi, K. L., & Bakris, G. L. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.004 · Cited by 8
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
Liang, Y.-H., Wang, J., Zhou, Y., Jiang, X.-J., Jiang, H., & Huang, C.-X. (2004) · Life Science · doi:10.1016/j.lfs.2004.04.012 · Cited by 8
Systemic Aldosterone, But Not Angiotensin II, Plays a Pivotal Role in the Pathogenesis of Renal Injury in Chronic Nitric Oxide-Deficient Male Rats.
Suehiro, T., Tsuruya, K., Ikeda, H., Toyonaga, J., Yamada, S., Noguchi, H., Tokumoto, M., & Kitazono, T. (2015) · Endocrinology · doi:10.1210/en.2014-1369 · Cited by 7
Complete inhibition of the renin–angiotensin–aldosterone system; where do we stand?
Chen, S. S., Seliger, S. L., & Fried, L. F. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000043 · Cited by 5
“‘Aldosterone escape’ is also observed with both ACEI and ARB, possibly due to increased serum potassium levels, ACE escape, or increased angiotensin II competing with the angiotensin 1 receptor or binding to angiotensin 2 receptor [7,10].”
Background
Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension
Kota, S., Jammula, S., Kota, S. K., Meher, L., & Modi, K. (2012) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-012-0063-5 · Cited by 7
“rone levels and degree of proteinuria [22], and others supported this association [23].”
Background
Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker
Miyashita, Y., Mifune, M., Kubota, E., Itoh, H., & Saito, I. (2009) · Clinical and experimental hypertension · doi:10.3109/10641960903407017 · Cited by 7
“During the long-term treatment with an ACE-I or ARB, the plasma level of aldosterone decreased once and then tended to increase and blunt the effectiveness of an ACE-I and/or ARB, which is called a aldosterone breakthrough phenomenon(16).”
BackgroundInfluential
The Role of Na+-H+Exchanger Isoform 1 in Aldosterone-Induced Glomerulosclerosis in Vivo
Zhang, M., Chen, J., Liu, S., Li, Y., Lin, S., & Gu, Y. (2009) · Renal Failure · doi:10.3109/08860220903134571 · Cited by 7
“system (RAS) inhibition and aldosterone blockade has been associated with decreased proteinuria and glomerulosclerosis in patients with chronic kidney diseases and reduced renal damage.([20,21]) Terada et al.”
Background
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children
Ku, E., & Campese, V. (2009) · Pediatric nephrology (Berlin, West) · doi:10.1007/s00467-009-1176-z · Cited by 7
“Similar incidences of aldosterone escape have been noted in patients with diabetic nephropathy [44].”
Background
Treatment of Hypertension in Patients with Renal Disease
Garg, J. P., & Bakris, G. L. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1022973928505 · Cited by 6
Mineralocorticoid receptor expression in human penile corpus cavernosum.
Kishimoto, T., Fukawa, T., Yamaguchi, K., Yamamoto, Y., Nakatsuji, H., Izaki, H., Takahashi, M., Fukumori, T., & Kanayama, H. (2013) · Journal of Medical Investigation · doi:10.2152/jmi.60.21 · Cited by 7
Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus
Rastogi, A., & Weir, M. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108515 · Cited by 7
The spectrum of plasma renin activity and hypertension diseases: Utility, outlook, and suggestions
Liu, Z., Jin, L., Zhou, W., & Zhang, C. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24738 · Cited by 11
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Cohen, S. B., Sternlicht, H., & Bakris, G. L. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01461-4 · Cited by 14
Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients
Shimoura, H., Tanaka, H., Matsumoto, K., Mochizuki, Y., Hatani, Y., Hatazawa, K., Matsuzoe, H., Ooka, J., Sano, H., Sawa, T., et al. (2016) · Heart and Vessels · doi:10.1007/s00380-016-0904-0 · Cited by 8
“It has been suggested that the aldosterone breakthrough is an important risk factor for cardiovascular disease progression including the progression of LVH, despite the use of ACE inhibitors or ARBs[35-37].”
Background
Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods
Roos, K., Hogner, A., Ogg, D., Packer, M. J., Hansson, E. L., Granberg, K. L., Evertsson, E., & Nordqvist, A. (2015) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-015-9880-1 · Cited by 6
“chronic kidney disease in the diabetic subpopulation [5–9].”
Background
The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis
Elnagar, N., Satoh, M., Hosaka, M., Asayama, K., Ishikura, K., Obara, T., Mano, N., Ohkubo, T., & Imai, Y. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.892117 · Cited by 5
“Therefore, a combination of eplerenone with ARB may be a rational treatment option (29).”
BackgroundInfluential
Synthesis of sterically encumbered 11β-aminoprogesterone derivatives and evaluation as 11β-hydroxysteroid dehydrogenase inhibitors and mineralocorticoid receptor antagonists.
Pandya, K., Dietrich, D., Seibert, J., Vederas, J., & Odermatt, A. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.068 · Cited by 6
Reducing Cardiovascular Events in High‐Risk Patients: The Challenge of Managing Hypertension in Patients With Diabetic Renal Disease
Toto, R. D. (2007) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2007.07723.x · Cited by 5
Aldosterone synthase (CYP11B2)344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy
Schjoedt, K. J., Lajer, M., Andersen, S., Tarnow, L., Rossing, P., & Parving, H. (2006) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510600548702 · Cited by 6
Cardiovascular risk in diabetic kidney disease: A model of chronic renal disease
Thomas, S. M., & Viberti, G. C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09803.x · Cited by 6
“Patients with type 2 diabetes and higher plasma aldosterone levels, despite inhibition of the renin-aldosterone system, tend to have worse albuminuria even with comparable blood pressure which is lowered by the addition of lowdose spironolactone (25 mg/day) [18].”
Background
Rein et diabète
Halimi, J. (2004) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2004.10.005 · Cited by 6
Controversy over renin–angiotensin–aldosterone system (RAAS) inhibitors treatment in nephrology and cardiovascular diseases
Donderski, R. Ł., Bednarski, R., & Manitius, J. (2020) · Arterial Hypertension · doi:10.5603/ah.a2020.0007 · Cited by 8
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes
Haller, H. G. (2022) · Herz · doi:10.1007/s00059-022-05138-2 · Cited by 4
“Also in other models of CKD (nephron reduction, diabetic nephropathy, glomerulopathies), mineralocorticoid receptor antagonists exert a positive effect [38, 39].”
Background
Glomerular Mesangial Cell pH Homeostasis Mediates Mineralocorticoid Receptor-Induced Cell Proliferation
Gekle, M., & Mildenberger, S. (2021) · Biomedicines · doi:10.3390/biomedicines9091117 · Cited by 7
Cardiac hypertrophy in chronic kidney disease—role of Aldosterone and FGF23
Hayashi, K., Suzuki, T., Sakamaki, Y., & Ito, S. (2018) · Renal Replacement Therapy · doi:10.1186/s41100-018-0152-0 · Cited by 5
“Further evidence has accrued that aldosterone, a traditional hormone regulating serum electrolyte balance, not only induces renal glomerular hypertension [8] but also causes cardiac hypertrophy [9, 10] and heart failure [11].”
BackgroundSelf-citation
The Impact of Cardiovascular Drugs on Glycemic Control: A Review
Grodzinsky, A., Arnold, S. V., Jacob, D., Draznin, B., & Kosiborod, M. (2016) · Endocrine Practice · doi:10.4158/ep161309.ra · Cited by 6
[Aldosterone and kidney diseases: an emergent paradigm with important clinical implications].
Bertocchio, J., & Jaisser, F. (2011) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2010.10.012 · Cited by 5
[Role of aldosterone in oxidative stress and renal injury].
Nishiyama, A., Kusaka, T., & Kitajima, H. (2007) · Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan · doi:10.1248/yakushi.127.1331 · Cited by 5
Urinary albumin excretion and the renin–angiotensin system in cardiovascular risk management
van de Wal, R. M. A., Voors, A. A., & Gansevoort, R. T. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.18.2505 · Cited by 6
“Furthermore, several studies provide evidence that spironolactone, a non-selective aldosterone receptor antagonist, has a renovascular protective effect [149-151].”
Background
Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
Campese, V., & Park, J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249690.88865.90 · Cited by 5
Managing diabetic nephropathy: recent studies
Lit, Y., & Meyer, T. W. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.mnh.0000214768.21911.62 · Cited by 5
Differential Effects of Antihypertensive Drugs on Renal and Glomerular Hemodynamics and Injury in the Chronic Nitric-Oxide-Suppressed Rat
Zhou, X., & Frohlich, E. D. (2005) · American Journal of Nephrology · doi:10.1159/000085358 · Cited by 6
“In addition, the phenomenon of ‘aldosterone escape’ has been suggested to participate during ACE-I therapy [ , , ,”
Background
Potential therapies mimicking the effects of glucagon‐like peptide‐1 for the treatment of Type 2 diabetes
Rachman, J. (2004) · Diabetic Medicine · doi:10.1111/j.1466-5468.2004.1180h.x · Cited by 6
Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: Possible involvement of bone morphogenetic protein-6 actions
Otani, H., Otsuka, F., & Makino, H. (2010) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.122.27 · Cited by 2
Cardiorenal Disease: A Clinical Intersection
Kalra, V., Mahajan, S., Agarwal, S. K., & Tiwari, S. C. (2005) · International Urology and Nephrology · doi:10.1007/s11255-004-1561-2 · Cited by 5
Use of finerenone in patients with chronic kidney disease at high risk of heart failure
Hakim, J. P., Handelsman, Y., & Banerjee, T. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156297 · Cited by 4
Future and Novel Compounds in the Treatment of Diabetic Nephropathy
Idzerda, N. M. A., Pena, M. J., de Zeeuw, D., & Heerspink, H. J. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_29 · Cited by 5
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria
Fogari, R., Mugellini, A., Zoppi, A., Gualtierotti, R., Lazzari, P., Derosa, G., & D'Angelo, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.848195 · Cited by 4
“It has been shown that an increase in plasma aldosterone levels, so-called aldosterone escape, occurs in approximately 40% of type 2 diabetic patients with early nephropathy despite the use of ACE inhibitors, which might be responsible for the late escape of these patients from the antiproteinuric effect observed with…”
Background
Up-Regulation of Renin-Angiotensin System in Diabetes and Hypertension: Implications on the Development of Diabetic Nephropathy
Casarini, D. E., Arita, D. Y., Sousa, T., Aparecida, F., Aragão, D. S., Rosa, R. M., Bertoncello, N. S. C., & Klein, F. (2012) · InTech eBooks · doi:10.5772/36852
“Sato et al (2003) in a study in patients with DM2 described that patients with aldosterone escape of 40% have higher albumin excretion than those without.”
Background
Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensin‐Converting Enzyme Inhibitors
Ritz, E. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00448.x · Cited by 4
New therapeutic agents for diabetic kidney disease
Agrawal, V., Kizilbash, S. H., & McCullough, P. A. (2008) · Therapy · doi:10.2217/14750708.5.4.553 · Cited by 4
Losartan in Marfan Syndrome—Beyond Blood Pressure Lowering
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B., Cooper, T. K., Myers, L. A., Klein, E. C., Liu, G., Calvi, C. L., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050508 · Cited by 4
Role of Aldosterone Blockade in the Management of Hypertension and Cardiovascular Disease
Epstein, M. M. (2004) · KARGER eBooks · doi:10.1159/000078714 · Cited by 3
Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control
Sarzani, R., Dessı̀-Fulgheri, P., & Rappelli, A. (2004) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200411020-00004 · Cited by 4
Structured education programmes and Type 2 diabetes
Cavan, D., & Cradock, S. (2004) · Diabetic Medicine · doi:10.1111/j.1466-5468.2004.1180e.x · Cited by 4
Endocrine Causes of Hypertension—Aldosterone
Weiner, I. D., & Wingo, C. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-05876-6.00038-1 · Cited by 4
Aldosterone and its Cardiovascular Effects
Garg, R., & Adler, G. K. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-373870-7.00023-5 · Cited by 3
Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity
Okamura, K., Matsushima, M., Takamiya, Y., Okuda, T., Sako, H., Udo, A., Taniguchi, K., Morisaki, S., Imamura, I., Urata, H., et al. (2024) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6058 · Cited by 3
“Blocking the RAAS often causes unexpected problems in vivo , such as the aldosterone breakthrough phenomenon [22].”
Mineralocorticoid receptor antagonists and reno‐protection: What's the evidence & where do they fit? A guide for non‐specialists
Bakris, G. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15617 · Cited by 3
“25,26 This breakthrough is associated with an accelerated decline in eGFR and increased albuminuria in patients with diabetic kidney disease.”
Maladie rénale chronique et diabète de type 2. Histologie, pathogénie et stades évolutifs
Monnier, L., Halimi, S., & Colette, C. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.10.003 · Cited by 4
Antialbuminuric effect of eplerenone in comparison to thiazide diuretics in patients with hypertension
Sawai, T., Dohi, K., Fujimoto, N., Okubo, S., Isaka, N., Ichikawa, T., Makino, K., Okamoto, S., Koyabu, S., Kitamura, T., et al. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13054 · Cited by 4
Review: Dual blockade of the renin angiotensin system in diabetes — rationale and risks
Kumar, R., & Winocour, P. H. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050050501 · Cited by 4
The Polypill and Type 2 diabetes
Gale, E. (2004) · Diabetic Medicine · doi:10.1111/j.1466-5468.2004.1180d.x · Cited by 3
[Mechanisms responsible for the renoprotective effects of renin-angiotensin inhibitors].
Nishiyama, A. (2012) · Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan · doi:10.1248/yakushi.132.455 · Cited by 3
Pathophysiology and Pathogenesis of Diabetic Nephropathy
Wolf, G., Sharma, K., & Ziyadeh, F. N. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50081-4 · Cited by 4
Tratamiento del enfermo hipertenso con nefropatía diabética
Ramos, P. M., & Juanatey, J. R. G. (2007) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(07)75234-2 · Cited by 3
Impact of Selective Peroxisome Proliferator-Activated Receptor (PPAR)-α Modulators and Fibrates on Microvascular Disease: Is There Still Room?
Marinho, L. L., Ribeiro, M. L., Lawler, P. R., Iatan, I., Godoy, L. C., Rached, F. H., & Maranhão, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01292-0 · Cited by 3
Treatment Goals in Diabetic Nephropathy
Vervoort, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_25 · Cited by 2
The role of aldosterone antagonism agents in diabetic kidney disease.
Wombwell, E., & Naglich, A. C. (2015) · Journal of renal care · doi:10.1111/jorc.12085 · Cited by 2
Mineralocorticoid receptor blockade--a novel approach to fight hyperkalaemia in chronic kidney disease
Ritz, E., & Pitt, B. (2013) · Clinical Kidney Journal · doi:10.1093/ckj/sft084 · Cited by 2
“Aldosterone is the cause of such renal ‘escape’ in diabetic nephropathy [18] and other forms of proteinuric nephropathy and this is also true in advanced renal failure [19].”
Background
MR blockade in patients with chronic renal disease--not the more the merrier, but the earlier the better.
Lepenies, J., & Quinkler, M. (2006) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfl371 · Cited by 2
Das Renin–Angiotensin–Aldosteron–System – komplexer als bisher gedacht
Wolf, G. (2005) · Medizinische Klinik · doi:10.1007/s00063-005-1071-8 · Cited by 2
“Größere kontrollierte Studien mit harten Endpunkten bezüglich einer Verbesserung der Nierenfunktion und Reduktion der Progression zur terminalen Niereninsuffizienz stehen jedoch noch aus.”
Die diabetische Nephropathie
Meier, M., & Haller, H. (2004) · Herz · doi:10.1007/s00059-004-2610-4 · Cited by 2
Compelling drug indications in diabetic and nondiabetic nephropathy
Ritz, E., Dikow, R., & Zeier, M. G. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0024-6 · Cited by 2
“In diabetic patients with aldosterone “escape”—that is, secondary rise of urine aldosterone excretion after an initial decrease with ACEIs—administration of a mineralocorticoid receptor blocker, such as spironolactone or epleronone, decreases albumin excretion again [ 44 ].”
Background
Distinct responses of membranoproliferative glomerulonephritis-related proteinuria to spironolactone with and without angiotensin II blockade.
Yonemura, K., Yasuda, H., & Hishida, A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-9-200311040-00022-w3 · Cited by 2
Oportunidades clínicas del bloqueo aldosterónico en la hipertensión arterial
Pérez, A. P. (2003) · doi:10.1016/s1889-1837(03)71419-6 · Cited by 2
Beyond current standards: combination therapy and emerging targets in diabetic kidney disease
Lee, J., Yu, M., & On behalf of the Korean Diabetic Kidney Disease Study Group (2026) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.26.234 · Cited by 1
“Thus, MRAs and ASIs should be viewed as complementary rather than competing strategies, representing down-stream receptor blockade and upstream hormone synthesis inhibition, respectively [13,33,34].”
Nonsteroidal mineralocorticoid receptor antagonist in diabetic kidney disease: mechanistic insights and clinical integration
Jeong, H. Y., Lee, E. Y., & On behalf of the Korean Diabetic Kidney Disease Study Group (2026) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.26.233
“Aldosterone is a key contributor to the initiation and progression of DKD, independent of blood pressure [10,11].”
The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?
Donderski, R. Ł., & Manitius, J. (2019) · Arterial Hypertension · doi:10.5603/ah.a2018.0016 · Cited by 2
DRUGS FOR DIABETIC NEPHROPATHY- FULL REVIEW
Soni, N. (2017) · doi:10.20959/wjpps20177-9637 · Cited by 1
“8) RAS farnesylation Inhibitors 9) Aldose Reductase inhibitors 10) Oligodonucleotide against p 22 11) EGFR Inhibitors 12) PLC gamma 1 inhibition 13) Inhibition of osteopontin 14) P38 INHIBITORS 15) NADPH OXIDASE INHIBITOR 16) Hippo pathway Inhibitors 17) Xanthine oxidase inhibitor 18) Src inhibitors 19) Matrix metallo…”
Etiology and management of hypertension in chronic kidney disease
Singh, S. K. (2012) · Clinical Queries Nephrology · doi:10.1016/j.cqn.2012.09.007 · Cited by 3
Effect of Spironolactone on Chronic Allograft Nephropathy in Rats
Cogar, S. M., Schmiedt, C., Brown, C., Michel, L., enplas, Chessman, C., & Hurley, D. (2012) · doi:10.4172/2161-0959.s4-004 · Cited by 1
“Acutely, common RAAS modification strategies will result in systemic suppression of aldosterone, however this suppression is often not durable; this unsustained suppression is termed ‘aldosterone escape,’ and occurs nearly 40% of the time in humans receiving angiotensin converting enzyme inhibitor therapy [3].”
Background
Effect of Spironolactone on Diastolic Heart Function in Patients with Chronic Kidney Disease
Sengul, E., Şahin, T., Çaglayan, Ç., & Yılmaz, A. (2010) · doi:10.5262/tndt.2010.1003.06 · Cited by 1
“ACE inhibitörü ve ARB’ler ile yapılan tedaviler sırasında hastaların önemli bir kısmında aldosteron düzeyi baskılanamamakta ve aldosteronun hedef organlardaki olumsuz etkilerinin devam etmesine yol açmaktadır (5).”
Background
Hipertensão e condições clínicas associadas
Filho, S. F., de Paula, R. B., Avezum, Á., de Freitas, G. R., Francischetti, E. A., Batista, M. C., de Carvalho, M. H. C., Zanella, M. T., Gomes, M. D. B., Wajngarten, M., et al. (2010) · Brazilian Journal of Nephrology · doi:10.1590/s0101-28002010000500011
Cardiac benefits of mineralocorticoid receptor inhibition in renal failure.
Graf, K., Hucko, T., & Stawowy, P. (2008) · HYPERTENSION · doi:10.1161/hypertensionaha.108.115733 · Cited by 1
Mineralocorticoid Antagonists in Heart Failure and Chronic Renal Failure
Brown, N. (2007) · doi:10.3109/9781420020946-24 · Cited by 1
Das Renin-Angiotensin-Aldosteron-System als Zentraler Mediator der Progression der Niereninsuffizienz
Pöschel, K. A., & Wolf, G. (2006) · Der Nephrologe · doi:10.1007/s11560-006-0041-3 · Cited by 2
“[36] zeigten unter Kombinationstherapie mit einem ACE-Hemmer und Spironolacton einen Rückgang der Proteinurie bei Patienten mit diabetischer Nephropathie.”
Background
Mathematical modelling of the course of chronic renal failure.
Rashidi, A., & Khodarahmi, I. (2006) · Nephrology, Dialysis and Transplantation · doi:10.1093/ndt/gfl391 · Cited by 1
Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
Coca, S. G., & Perazella, M. A. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.3.3.497 · Cited by 1
(Alte) Neue Medikamente: Aldosteron-Antagonisten zur Behandlung kardiovaskulärer und nephrologischer Erkrankungen
Fiebeler, A., & Luft, F. (2004) · doi:10.1055/s-2004-835293 · Cited by 1
Antihypertensive drugs and the kidney
Nadim, M. K., Dua, R., & Campese, V. M. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0046-3 · Cited by 5
Providing free care to the uninsured: how much should physicians give?
Astor, A., & Sreenivasan, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-9-200311040-00022-w2 · Cited by 1
Approach to Chronic Kidney Disease in the Diabetic Patient
Afshinnia, F., & Brosius, F. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00043-3 · Cited by 1
Blockade of the renin–angiotensin system for the primary prevention of diabetic nephropathy
Thomas, M. C., & MacGinley, R. (2011) · Diabetes Management · doi:10.2217/dmt.11.69 · Cited by 1
Atherosclerotic Risk Factors
DeLoach, S. S., & Mohler, E. R. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00029-9
Diabetic Nephropathy in Childhood and Adolescence (II) ; Pathology and Pathophysiology
Ha, T. (2009) · Journal of the Korean Society of Pediatric Nephrology · doi:10.3339/jkspn.2009.13.2.99 · Cited by 1
Role of Glomerular Pressure in Progression
Adamczak, M., & Ritz, E. (2008) · Elsevier eBooks · doi:10.1016/b978-012088488-9.50091-7 · Cited by 1
Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events
Lakkis, J. I., & Weir, M. R. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0258-5.50142-3
Néphroangiosclérose
Beaufils, M. (2005) · Encyclopédie médico-chirurgicale. Néphrologie · doi:10.1016/j.emcnep.2005.07.001 · Cited by 2

Authors: Sato, A., Hayashi, K., Naruse, M., & Saruta, T.
Affiliations: Keio University (JP)
From the Department of Internal Medicine, Mito Red Cross Hospital (A.S.), Ibaraki; the Department of Internal Medicine, Keio University (K.H., T.S.), Tokyo; and the Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women’s Medical University (M.N.), Tokyo, Japan.
ORCID: Naruse, Mitsuhide
Venue: Hypertension
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2003-01
Volume: 41
Issue: 1
Pages: 64-68
ISSN: 0194-911X (ISSN-L)
1524-4563
DOI: 10.1161/01.hyp.0000044937.95080.e9
OpenAlex: W2163709605
Cited by: 466
References: 0
Citations by year: 2026: 7 · 2025: 8 · 2024: 5 · 2023: 15 · 2022: 20 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 11 · 2017: 4 · 2016: 13 · 2015: 16 · 2014: 20 · 2013: 19 · 2012: 28
FWCI: 28.03
Type: journal article
Language: en
Open access: closed
Locations: Hypertension (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Keywords: aldosterone escape, aldosterone blockade, spironolactone, ACE inhibitors, diabetic nephropathy, type 2 diabetes, urinary albumin excretion, proteinuria, left ventricular mass, renin-angiotensin system
MeSH terms: Albuminuria, Aldosterone, Mineralocorticoid Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Therapy, Combination, Female, Heart Ventricles, Humans, Male, Middle Aged, Spironolactone, Ultrasonography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks